Together with the notion that TEMs were found to accumulate preferentially in the proximity of CRC metastases in the human liver, these results indicate that administering autologous genetically engineered HSPCs leading to intrahepatic delivery of IFNα by TEMs may represent a novel strategy to treat patients with CRC. This evidence concerns the gene IFNA1 and colorectal carcinoma.